Trulicity vs Retatrutide: What to Do When One Fails

What Is Trulicity (Dulaglutide) and Where Does It Fall Short?

Trulicity is a once-weekly GLP-1 receptor agonist approved by the FDA in 2014 for glycemic control in type 2 diabetes, and it carries a cardiovascular risk-reduction indication based on the REWIND trial. Its ceiling for weight loss is modest. In AWARD-11 (N=1,842), the 4.5 mg high-dose arm produced only 10.0% body weight reduction at 52 weeks, which lags behind semaglutide 2.4 mg and far behind retatrutide [1].

Mechanism and Approved Doses

Dulaglutide binds the GLP-1 receptor on pancreatic beta cells and in the hypothalamus, slowing gastric emptying, reducing glucagon, and increasing satiety signaling [2]. The approved dose range runs from 0.75 mg weekly (starting dose for glycemic control) up to 4.5 mg weekly (the highest commercially available dose, approved in 2020). Titration takes roughly 4 to 8 weeks per step to minimize nausea.

REWIND Cardiovascular Outcome Data

The REWIND trial (N=9,901) randomized patients with type 2 diabetes and either established cardiovascular disease or cardiovascular risk factors to dulaglutide 1.5 mg weekly versus placebo [3]. Over a median 5.4-year follow-up, dulaglutide reduced the primary MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by a relative 12% (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) [3]. That cardiovascular benefit is absent from retatrutide's current data package, since no CVOT has been completed for retatrutide.

Defining "Failure" for Dulaglutide

The American Diabetes Association Standards of Care define therapeutic intensification as warranted when HbA1c remains above individualized targets after 3 months at the maximally tolerated dose [4]. For weight management, the Obesity Society considers less than 5% body weight reduction after 6 months at the maximum tolerated dose a reasonable threshold for switching agents [5]. Trulicity commonly fails on weight targets even when glycemic control is adequate, which creates a distinct switching scenario covered below.

What Is Retatrutide and What Does the Phase 2 Data Show?

Retatrutide (LY3437943) is an investigational once-weekly subcutaneous peptide that simultaneously agonizes GIP (glucose-dependent insulinotropic polypeptide), GLP-1, and glucagon receptors. That triple mechanism produces weight loss substantially greater than any single or dual agonist approved as of mid-2025. Phase 2 results published in the New England Journal of Medicine in 2023 showed 24.2% mean body weight reduction at 48 weeks in the 12 mg dose group [6].

The Phase 2 Trial Design

Jastreboff et al. Randomized 338 adults with obesity (BMI ≥30 kg/m2 or ≥27 kg/m2 with at least one weight-related comorbidity) and without diabetes to retatrutide doses of 1 mg, 4 mg, 8 mg, or 12 mg weekly, or placebo, for 24 weeks with an optional 24-week extension [6]. The 12 mg arm reached 24.2% mean weight loss by week 48, and 26% of participants in that arm lost more than 30% of body weight [6]. For context, semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) [7].

The Glucagon Receptor Component: What It Adds

The glucagon receptor agonism in retatrutide increases resting energy expenditure by approximately 10 to 15% above GLP-1 alone in preclinical models [8]. In the Phase 2 trial, lean mass loss was proportionally lower than seen with GLP-1 monotherapy, suggesting the glucagon axis may preserve metabolic rate during aggressive caloric restriction [6]. This is speculative based on Phase 2 data alone. Definitive body-composition data are expected from the Phase 3 TRIUMPH program.

Adverse Events and Tolerability

GI adverse events (nausea, vomiting, diarrhea, constipation) occurred in up to 45% of participants in the 12 mg arm of the Phase 2 trial [6]. Most were mild to moderate and peaked during dose escalation. Heart rate increased by a mean of 4 to 7 beats per minute across dose groups, consistent with GLP-1 class effects [6]. Injection-site reactions were rare. No severe hypoglycemia occurred in non-diabetic participants, though the trial excluded patients on insulin [6].

Head-to-Head Comparison: Trulicity vs Retatrutide

No published randomized head-to-head trial has directly compared dulaglutide to retatrutide. The comparison below synthesizes data from individual trials conducted in partly overlapping populations.

Weight Loss Outcomes

| Metric | Trulicity 4.5 mg | Retatrutide 12 mg | |---|---|---| | Mean weight loss | 10.0% at 52 weeks (AWARD-11) [1] | 24.2% at 48 weeks (Phase 2) [6] | | Patients losing ≥10% body weight | 42% (AWARD-11) [1] | 83% (Phase 2) [6] | | Patients losing ≥15% body weight | 21% (AWARD-11) [1] | 64% (Phase 2) [6] | | Population | T2D (HbA1c 7.5 to 10.5%) | Obesity without diabetes |

The population difference matters. Trulicity's AWARD-11 data come from patients with type 2 diabetes, who tend to lose less weight on GLP-1 agonists than non-diabetic individuals [9]. The comparison above therefore likely understates the true between-drug difference in a mixed clinical population.

Glycemic Efficacy

Dulaglutide 4.5 mg reduced HbA1c by 1.87 percentage points from a baseline mean of 8.6% in AWARD-11 [1]. Retatrutide's Phase 2 diabetes sub-analyses showed HbA1c reductions of up to 2.4 percentage points at the 12 mg dose in a Phase 2 study in type 2 diabetes (Rosenstock et al., NEJM 2023) [10]. Direct comparison is difficult given different baseline HbA1c distributions across trials.

Cardiovascular and Long-Term Safety

Trulicity has a 5.4-year CVOT demonstrating MACE reduction [3]. Retatrutide has no CVOT. The FDA is unlikely to approve retatrutide without a CVOT commitment, and Phase 3 TRIUMPH program results are expected in 2026 at the earliest. Prescribers managing patients with established atherosclerotic cardiovascular disease or heart failure should consider this evidence gap carefully before any switch.

When Does Trulicity "Fail"? Clinical Criteria

Three distinct failure patterns justify switching or adding an agent.

Pattern 1: Inadequate Glycemic Response

A clinician should consider switching if the patient's HbA1c remains >0.5 percentage points above target after 3 months at the maximum tolerated dulaglutide dose [4]. The ADA 2024 Standards of Care state: "For patients not achieving glycemic targets, consider adding or switching to a more effective agent, taking into account the cardiovascular and renal outcome data" [4]. At maximum dose (4.5 mg), roughly 30% of patients in AWARD-11 still had HbA1c above 7% at 52 weeks [1].

Pattern 2: Inadequate Weight Response

Weight-related switching criteria differ from glycemic criteria. Less than 5% body weight reduction after 6 months at the maximum tolerated dose is the commonly used threshold, per Obesity Society guidance [5]. Trulicity produces clinically meaningful weight loss for many patients, but a large subset does not reach the 5 to 10% threshold associated with meaningful cardiometabolic benefit [11].

Pattern 3: Intolerable Side Effects

Persistent nausea, vomiting, or gastroparesis-like symptoms at any dose level warrant switching to an alternative with a different dose-titration profile or formulation. Switching from a GLP-1 mono-agonist to a triple agonist like retatrutide does not eliminate GI risk. Retatrutide's GI adverse-event rate in Phase 2 (45% in the 12 mg arm) was higher than semaglutide's rate of 44.2% in STEP-1 [7], and both are higher than dulaglutide's rate in REWIND (approximately 20 to 25%) [3].

Should You Switch from Trulicity to Retatrutide?

The decision to switch from dulaglutide to retatrutide depends on five factors: regulatory availability, clinical indication (diabetes vs. Obesity), cardiovascular risk profile, GI tolerability history, and access or cost. Here is a structured decision framework.

Step 1: Confirm Regulatory Status Before Prescribing

Retatrutide is not FDA-approved as of mid-2025. It is available only through clinical trials or, in some jurisdictions, compounding pharmacies operating under specific protocols [12]. Prescribing unapproved compounded retatrutide carries regulatory and liability considerations. Clinicians should check the FDA's current drug approval database before initiating any prescription [12].

Step 2: Assess the Primary Therapeutic Goal

If the primary goal is cardiovascular risk reduction in established ASCVD, dulaglutide (or semaglutide, which has SUSTAIN-6 and SELECT data) remains the evidence-based choice [3, 13]. If the primary goal is weight reduction in obesity with or without diabetes, retatrutide's Phase 2 data suggest it may offer a substantially larger weight reduction once approved [6]. Switching to an unapproved agent purely for weight is premature outside a clinical trial.

Step 3: Evaluate GI Tolerability History

Patients who discontinued dulaglutide because of intolerable GI side effects face similar or higher GI risk with retatrutide. A slower titration schedule, starting at 2 mg retatrutide weekly and titrating over 24 weeks to the target dose, reduced dropout in Phase 2 [6]. Clinicians should document whether prior GI intolerance was dose-dependent (more manageable with slower titration) or dose-independent (likely to recur regardless).

Step 4: Review the Washout and Transition Protocol

No FDA-approved switching guideline exists for dulaglutide to retatrutide. Based on pharmacokinetic data from Phase 2 and the dulaglutide prescribing information, the following approach is reasonable pending formal guidance [14, 6]:

• Complete the last dulaglutide dose on its scheduled day.
• Allow a 1-week gap (one half-life of dulaglutide is approximately 5 days) before starting retatrutide at the lowest available dose (2 mg weekly in Phase 2) [14].
• Titrate retatrutide every 4 weeks as tolerated, consistent with the Phase 2 escalation schedule [6].
• Recheck HbA1c and body weight at 12 weeks to confirm response.

Step 5: Monitor for Additive Cardiovascular Effects

Both agents increase resting heart rate. Dulaglutide increased mean heart rate by 2 to 3 beats per minute in REWIND [3]. Retatrutide increased mean heart rate by 4 to 7 beats per minute in Phase 2 [6]. Patients with pre-existing sinus tachycardia or a personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not receive either agent [14].

Real-World Switching Scenarios

Scenario A: Trulicity Controlled HbA1c but Weight Loss Stalled

A 52-year-old man with type 2 diabetes (HbA1c 6.8%) and class II obesity (BMI 38 kg/m2) lost only 2.1 kg after 6 months on dulaglutide 4.5 mg. His diabetes is controlled, but his weight target (at least 10% reduction) has not been met. Options include adding tirzepatide (approved for both T2D and obesity, with 22.5% weight loss at 72 weeks in SURMOUNT-1) [15], switching to semaglutide 2.4 mg (approved for weight management), or enrolling in a retatrutide Phase 3 trial. Adding or switching to an approved agent with stronger weight data is clinically defensible today.

Scenario B: Trulicity Caused Intolerable Nausea

A 44-year-old woman with class I obesity (BMI 31 kg/m2) and prediabetes discontinued dulaglutide 1.5 mg after 8 weeks because of persistent nausea. Slower titration starting at 0.75 mg was not offered initially. Before switching to any other GLP-1 class drug, a slow re-titration trial of dulaglutide (0.75 mg for 8 weeks before any increase) should be attempted. If GI intolerance recurs, oral semaglutide (Rybelsus) at 3 mg daily may be better tolerated in some patients because of lower peak plasma concentrations compared to subcutaneous formulations [16].

Scenario C: Trulicity Produced Adequate Weight Loss but CVOT Data Are Needed

A 67-year-old woman with type 2 diabetes and recent MI wants to switch to retatrutide after reading about its weight loss data. Dulaglutide 1.5 mg is reducing her HbA1c by 1.1 percentage points and her weight by 7%. The REWIND trial's demonstrated MACE reduction of 12% [3] is a concrete clinical benefit not available from retatrutide. Switching is not recommended in this patient until retatrutide CVOT data are published.

Dosing Reference: Trulicity vs Retatrutide

| Parameter | Trulicity (Dulaglutide) | Retatrutide | |---|---|---| | Route | Subcutaneous, once weekly | Subcutaneous, once weekly | | Starting dose | 0.75 mg | 2 mg (Phase 2 protocol) | | Maximum dose | 4.5 mg | 12 mg (Phase 2) | | Titration interval | Every 4 weeks | Every 4 weeks | | Approved indication | T2D, CV risk reduction | Not approved (Phase 3) | | Storage | Refrigerated or room temp (up to 14 days) | Refrigerated (Phase 2 trial supply) | | Pen device | Single-dose autoinjector | Single-dose autoinjector (trial formulation) |

What the Guidelines Currently Say

The ADA 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred second-line agents after metformin in patients with type 2 diabetes and atherosclerotic cardiovascular disease [4]. The document specifically names dulaglutide among agents with Level A evidence for cardiovascular risk reduction [4]. The ADA states: "GLP-1 receptor agonists are recommended over other diabetes medications due to their cardiovascular and renal benefits in high-risk patients" [4].

The Endocrine Society's 2023 Obesity Pharmacotherapy Guidelines note that agents producing greater than 15% weight reduction offer meaningfully better long-term weight maintenance and comorbidity resolution, and encourage clinicians to consider switching when initial therapy produces less than 5% weight reduction at 6 months [17]. Neither guideline addresses retatrutide by name because approval is pending.

The FDA's guidance on drug development for obesity (2023) requires Phase 3 trials to demonstrate at least 5% greater weight loss versus placebo and at least 35% of treated patients losing more than 5% of body weight [18]. Retatrutide's Phase 2 results substantially exceed both thresholds in the 8 mg and 12 mg arms [6].

Key Safety Considerations Before Any Switch

Thyroid C-Cell Risk

Both dulaglutide and retatrutide carry a class warning for thyroid C-cell tumors based on rodent studies [14]. The FDA requires a boxed warning for both GLP-1-containing agents stating they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 [14]. Switching between agents in the same class does not eliminate this risk.

Pancreatitis

Acute pancreatitis has been reported with all GLP-1 agonists, though causal relationship remains debated [19]. The prescribing information for dulaglutide recommends discontinuing the drug if pancreatitis is confirmed [14]. Retatrutide's Phase 2 trial reported no cases of pancreatitis in 338 participants, though the sample size is too small to characterize rare events [6].

Renal Function

Dulaglutide does not require dose adjustment for renal impairment and showed renoprotective effects in a pre-specified REWIND sub-analysis (HR 0.85, 95% CI 0.77 to 0.93 for the composite renal outcome) [20]. Retatrutide's renal safety profile is not yet defined in chronic kidney disease populations [6].